MUMBAI (Reuters) - Ranbaxy Laboratories, India's biggest generic drugmaker by revenue, reported a narrower net loss in the latest quarter helped by ramped-up sales of two acne drugs in the United States.
Ranbaxy, majority owned by Japan's Daiichi Sankyo Co, on Wednesday said net loss in October-December was 1.59 billion rupees compared with a loss of 4.92 billion rupees a year earlier.
Net sales rose 7 percent to 28.59 billion rupees, the company said in a statement.
The United States, Ranbaxy's biggest export market, has recently banned the import of drugs from the company's India plants due to quality concerns.
(Reporting by Sumeet Chatterjee; Editing by Christopher Cushing)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app